TOKYO--(BUSINESS WIRE)--As represented by prof. Yamanaka widely known for development of iPS
cells, the Japanese academia is rich in bio/pharma-related seeds.
Not only drug discovery seeds, various seeds are still hidden in the Japanese academia, such as seeds in early research fields and drug discovery support seeds.
Though the Japanese pharma & bio industry has been said not to be very eager for business-academia collaboration, the situation is fast-changing now. Being at the major turning point toward open innovation, the whole Japanese pharma & bio industry will gather at "BIO tech 2012" for PARTNERING in coming April.
For BIO tech 2012, a large number of pharmaceutical companies have
pledged their support as Sponsors
– from mega pharmaceuticals like MSD, Roche, sanofi and NOVARTIS
to Japanese major pharmaceutical companies as Takeda
Pharmaceutical, Astellas Pharma, etc. They are also actively
welcoming appointments for on-site meetings at BIO tech 2012, seeking to
discover seeds and find partners among the Japanese academia.
Why do they choose BIO tech 2012 as the best platform for partnering? "Academic Forum" held inside it holds the key, which will be renewed and almost double its scale from the previous time.
- What is Academic Forum? -
Renewed as a platform for "business-academia collaboration", it attracts a large number of presenters from universities and research institutes, who will disclose their latest research achievements here.
The themes cover 11 fields, from [Drug Discovery Seeds], drug discovery support seeds as [Drug Discovery Tools] & [Research Tools] to hot topics like [Tissue Engineering], [Cancer], [Immunology/Vaccine], etc.
<> Presentation Title / Presenters (excerpt from 300* sessions)
|- Anti-inflammatory protein Thioredoxin Hybrid Translational Research|
KYOTO UNIVERSITY, Institute for Virus Research /
Ewha Womans Univ, Dr. Junji Yodoi
|- Semiconductor-based biosensing platform for clinical diagnosis and drug discovery|
|The University of Tokyo, Department of Materials Engineering,|
Dr. Toshiya Sakata
|- Application of Neoglycolipids for Cancer and Autoimmune Diseases by Regulating Immune System|
|RIKEN, Research Center for Allergy and Immunology|
Dr. Hiroshi Watarai
<> Pharma Company Sponsors below and many more will join partnering at BIO tech 2012.
|AJINOMOTO PHARMACEUTICALS, Astellas Pharma, AstraZeneca, Chugai Pharmaceutical,|
|DAIICHI SANKYO, Dainippon Sumitomo Pharma, Eli Lilly Japan, F. Hoffmann-La Roche,|
|JANSSEN PHARMACEUTICAL, KAKEN PHARMACEUTICAL, KYORIN Pharmaceutical,|
|Meiji Seika Pharma, Mitsubishi Tanabe Pharma, NIPPON SHINYAKU, NOVARTIS PHARMA,|
sanofi-aventis, Takeda Pharmaceutical (as of March 18th)
Of course, above sponsors are not the only ones who are eager to find
seeds/partners in Japan. Other pharmaceutical companies and investors
from over the world will visit BIO tech 2012 seeking for business
opportunities (28,000 visitors expected). Considering BIO tech 2012 as
the most important platform to explore the Japanese & Asian market, many
companies will join Partnering here. By staggering show dates with
respect to other bio events in Europe and the US, the 2012 show is
expected to gather an increased number of overseas attendees.
>> Join Partnering at BIO tech 2012
[ About BIO tech 2012 (April 25 – 27, Tokyo) ]
Asia's largest bio event consisting of Partnering, Conference and Exhibition.
Conference with total 350* sessions & Exhibition gathering 650* exhibitors are also must-attend events to keep up with the current Asian bio industry. （*expected）
>> For more information / FREE Invitation Request
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50218572&lang=en